It is marketed as Azilect for treating Parkinsons disease either as monotherapy in early stages or adjunctive therapy with levodopa in moderate-to-advanced cases.

Selective irreversible MAO-B inhibitor that elevates striatal dopamine levels to improve motor function in Parkinsons patients with neuroprotective potential.

Rasagiline mesylate is the methanesulfonate salt of (R)-N-propargyl-1-aminoindan a white to off-white crystalline powder soluble in water featuring an indane ring with a propargylamine side chain.